e-therapeutics plc

Equities

ETX

GB00B2823H99

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:22 2024-04-26 am EDT			5-day change	1st Jan Change
9.8 ^GBX	+2.08%		-2.24%	+18.93%

Apr. 10	FTSE 100 Closes Up 0.3% as U.S. Uncertainty Boosts Appetite for U.K. Stocks	DJ
Apr. 10	E-Therapeutics says company faces lack of interest as UK listing	AN

E-Therapeutics working to capitalise on AI "blindside"

May 04, 2023 at 08:22 am EDT

(via NewsDirect)

e-Therapeutics PLC (AIM:ETX OTCQX:ETXPF) CEO Ali Mortazavi speaks to Thomas Warner following the release of the computational biology and chemistry company's full year results for 2022. Mortazavi says that it was a "tricky year for the biotechnology sector as a whole" but that eTherapeutics has shown "remarkable resilience."

He goes on to highlight the opportunity being presented to the company by the advent of large language models (LLMs) and GPT-4, saying that he's never before seen a technology "blindside the world" to such an extent.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about e-therapeutics plc

FTSE 100 Closes Up 0.3% as U.S. Uncertainty Boosts Appetite for U.K. Stocks	Apr. 10	DJ
E-Therapeutics says company faces lack of interest as UK listing	Apr. 10	AN
E-therapeutics plc Board Proposes Delisting from London Bourse's AIM	Apr. 10	MT
UK's e-therapeutics plc to Raise GBP29 Million from M&G, Investor	Apr. 10	MT
E-Therapeutics shares rise on strong financial year	Jan. 16	AN
E-Therapeutics shares to cease trading on OTCQX	Dec. 27	AN
UK's e-therapeutics to Cease Trading on OTCQX Best Market in US	Dec. 27	MT
EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production	Nov. 02	AN
E-therapeutics, Acturis Sign Deal for Therapy Support Insight	Nov. 02	MT
E-Therapeutics plc Announces Strategic Collaboration with Arcturis Data Limited	Nov. 02	CI
EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half	23-10-26	AN
E-therapeutics plc Reports Earnings Results for the Half Year Ended July 31, 2023	23-10-26	CI
The FTSE 100 Closes Up on Eased Oil Prices, Anticipation Over US Interest Rates Decision	23-09-20	DJ
Capital inks contract; Lansdowne becomes cash shell	23-09-20	AN
E-therapeutics Interim CFO Steps Down	23-09-20	MT
E-Therapeutics plc Announces Senior Management Update	23-09-20	CI
Virgin Wines warns sales will be below City forecasts	23-05-04	AN
FTSE 100 Closes Thursday Down on Further US Banking Concerns	23-05-04	DJ
UK Mutual Firms Need to Prepare For Worsening Credit Conditions, Says BOE Official	23-05-04	DJ
Earnings Flash (ETX.L) E-THERAPEUTICS Reports FY23 Revenue GBP475,000	23-05-04	MT
Earnings Flash (ETX.L) E-THERAPEUTICS Posts FY23 Loss GBX-1.54	23-05-04	MT
E-therapeutics plc Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-04	CI
Ormonde Mining acquires stake in Peak Nickel	23-02-07	AN
E-therapeutics Files 4 New Patent Applications	23-02-07	MT
Earnings Flash (ETX.L) E-THERAPEUTICS Reports Fiscal H1 Revenue GBP295,000	22-09-30	MT

Chart e-therapeutics plc

Duration

Period

More charts

Company Profile

e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.

Sector

Biotechnology & Medical Research

Calendar

07:30am - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
E-THERAPEUTICS PLC	+18.93%	71.33M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research